Review



antibodies against cannabinoid receptor 1  (Bioss)


Bioz Verified Symbol Bioss is a verified supplier
Bioz Manufacturer Symbol Bioss manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Bioss antibodies against cannabinoid receptor 1
    XXD medicated serum upregulates CB2 and Mfsd2a expression and downregulates <t>CB1</t> expression in the blood-brain barrier cell model. (A) and (B) Comparison of relative CB1 protein expression; (C) and (D) Comparison of relative CB2 protein expression; (E) and (F) Comparison of relative Mfsd2a protein expression; ** p < 0.01, * p < 0.05.
    Antibodies Against Cannabinoid Receptor 1, supplied by Bioss, used in various techniques. Bioz Stars score: 93/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antibodies against cannabinoid receptor 1/product/Bioss
    Average 93 stars, based on 4 article reviews
    antibodies against cannabinoid receptor 1 - by Bioz Stars, 2026-02
    93/100 stars

    Images

    1) Product Images from "Xixin Decoction’s novel mechanism for alleviating Alzheimer’s disease cognitive dysfunction by modulating amyloid-β transport across the blood–brain barrier to reduce neuroinflammation"

    Article Title: Xixin Decoction’s novel mechanism for alleviating Alzheimer’s disease cognitive dysfunction by modulating amyloid-β transport across the blood–brain barrier to reduce neuroinflammation

    Journal: Frontiers in Pharmacology

    doi: 10.3389/fphar.2024.1508726

    XXD medicated serum upregulates CB2 and Mfsd2a expression and downregulates CB1 expression in the blood-brain barrier cell model. (A) and (B) Comparison of relative CB1 protein expression; (C) and (D) Comparison of relative CB2 protein expression; (E) and (F) Comparison of relative Mfsd2a protein expression; ** p < 0.01, * p < 0.05.
    Figure Legend Snippet: XXD medicated serum upregulates CB2 and Mfsd2a expression and downregulates CB1 expression in the blood-brain barrier cell model. (A) and (B) Comparison of relative CB1 protein expression; (C) and (D) Comparison of relative CB2 protein expression; (E) and (F) Comparison of relative Mfsd2a protein expression; ** p < 0.01, * p < 0.05.

    Techniques Used: Expressing, Comparison

    XXD Modulates the P-gp/eCBs Axis in the Hippocampal CA1 Region of SAMP8 Mice; (A) and (B) Comparison of relative P-gp protein expression levels; (C) and (D) Comparison of relative CB1 protein expression levels; (E) and (F) Comparison of relative CB2 protein expression levels; (G) and (H) Immunohistochemical staining for P-gp in the hippocampal CA1 region of mice; (I) and (J) Immunohistochemical staining for CB1 in the hippocampal CA1 region of mice; (K) and (L) Immunohistochemical staining for CB2 in the hippocampal CA1 region of mice; (n = 6); scale bar: 20μm; images captured at ×400 magnification; ** p < 0.01, * p < 0.05.
    Figure Legend Snippet: XXD Modulates the P-gp/eCBs Axis in the Hippocampal CA1 Region of SAMP8 Mice; (A) and (B) Comparison of relative P-gp protein expression levels; (C) and (D) Comparison of relative CB1 protein expression levels; (E) and (F) Comparison of relative CB2 protein expression levels; (G) and (H) Immunohistochemical staining for P-gp in the hippocampal CA1 region of mice; (I) and (J) Immunohistochemical staining for CB1 in the hippocampal CA1 region of mice; (K) and (L) Immunohistochemical staining for CB2 in the hippocampal CA1 region of mice; (n = 6); scale bar: 20μm; images captured at ×400 magnification; ** p < 0.01, * p < 0.05.

    Techniques Used: Comparison, Expressing, Immunohistochemical staining, Staining



    Similar Products

    antibodies against cannabinoid receptor 1  (Bioss)
    93
    Bioss antibodies against cannabinoid receptor 1
    XXD medicated serum upregulates CB2 and Mfsd2a expression and downregulates <t>CB1</t> expression in the blood-brain barrier cell model. (A) and (B) Comparison of relative CB1 protein expression; (C) and (D) Comparison of relative CB2 protein expression; (E) and (F) Comparison of relative Mfsd2a protein expression; ** p < 0.01, * p < 0.05.
    Antibodies Against Cannabinoid Receptor 1, supplied by Bioss, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antibodies against cannabinoid receptor 1/product/Bioss
    Average 93 stars, based on 1 article reviews
    antibodies against cannabinoid receptor 1 - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    anti cb1 af594  (Bioss)
    93
    Bioss anti cb1 af594
    XXD medicated serum upregulates CB2 and Mfsd2a expression and downregulates <t>CB1</t> expression in the blood-brain barrier cell model. (A) and (B) Comparison of relative CB1 protein expression; (C) and (D) Comparison of relative CB2 protein expression; (E) and (F) Comparison of relative Mfsd2a protein expression; ** p < 0.01, * p < 0.05.
    Anti Cb1 Af594, supplied by Bioss, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti cb1 af594/product/Bioss
    Average 93 stars, based on 1 article reviews
    anti cb1 af594 - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    anti cannabinoid markers cb1  (Bioss)
    93
    Bioss anti cannabinoid markers cb1
    XXD medicated serum upregulates CB2 and Mfsd2a expression and downregulates <t>CB1</t> expression in the blood-brain barrier cell model. (A) and (B) Comparison of relative CB1 protein expression; (C) and (D) Comparison of relative CB2 protein expression; (E) and (F) Comparison of relative Mfsd2a protein expression; ** p < 0.01, * p < 0.05.
    Anti Cannabinoid Markers Cb1, supplied by Bioss, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti cannabinoid markers cb1/product/Bioss
    Average 93 stars, based on 1 article reviews
    anti cannabinoid markers cb1 - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    primary antibodies  (Bioss)
    93
    Bioss primary antibodies
    XXD medicated serum upregulates CB2 and Mfsd2a expression and downregulates <t>CB1</t> expression in the blood-brain barrier cell model. (A) and (B) Comparison of relative CB1 protein expression; (C) and (D) Comparison of relative CB2 protein expression; (E) and (F) Comparison of relative Mfsd2a protein expression; ** p < 0.01, * p < 0.05.
    Primary Antibodies, supplied by Bioss, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies/product/Bioss
    Average 93 stars, based on 1 article reviews
    primary antibodies - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    cb1  (Bioss)
    93
    Bioss cb1
    XXD medicated serum upregulates CB2 and Mfsd2a expression and downregulates <t>CB1</t> expression in the blood-brain barrier cell model. (A) and (B) Comparison of relative CB1 protein expression; (C) and (D) Comparison of relative CB2 protein expression; (E) and (F) Comparison of relative Mfsd2a protein expression; ** p < 0.01, * p < 0.05.
    Cb1, supplied by Bioss, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cb1/product/Bioss
    Average 93 stars, based on 1 article reviews
    cb1 - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    cannabinoid cb1 receptor  (Bioss)
    93
    Bioss cannabinoid cb1 receptor
    FIGURE 3 Mechanisms of the cannabidiol-induced vasorelaxation in isolated human pulmonary arteries. Concentration–response curve of the cannabidiol-induced vaso- relaxation after 30 min incubation (before precontraction) with antagonists of <t>CB1</t> AM251 (1 mmol/l), CB2 AM630 (1 mmol/l) (a) and endothelium-dependent relaxation to cannabinoids O-1918 (10 mmol/l), TRPV1 capsazepine (1 mmol/l) and TRPV4 RN1734 (20 mmol/l) (b) in endothelium-intact hPAs. The results are presented as the mean SEM of n tissue samples for each curve. In a few cases, SEM is smaller than or equal to the size of symbols. See Table 2 for n and the statistical analysis if not stated here. Representative CB1 (c), CB2 (d), TRPV1 (e) and GPR18 (f) immunoreactivity. Scale bars: 50 mm. hPAs, human pulmonary arteries; SEM, standard error of the mean.
    Cannabinoid Cb1 Receptor, supplied by Bioss, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cannabinoid cb1 receptor/product/Bioss
    Average 93 stars, based on 1 article reviews
    cannabinoid cb1 receptor - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    XXD medicated serum upregulates CB2 and Mfsd2a expression and downregulates CB1 expression in the blood-brain barrier cell model. (A) and (B) Comparison of relative CB1 protein expression; (C) and (D) Comparison of relative CB2 protein expression; (E) and (F) Comparison of relative Mfsd2a protein expression; ** p < 0.01, * p < 0.05.

    Journal: Frontiers in Pharmacology

    Article Title: Xixin Decoction’s novel mechanism for alleviating Alzheimer’s disease cognitive dysfunction by modulating amyloid-β transport across the blood–brain barrier to reduce neuroinflammation

    doi: 10.3389/fphar.2024.1508726

    Figure Lengend Snippet: XXD medicated serum upregulates CB2 and Mfsd2a expression and downregulates CB1 expression in the blood-brain barrier cell model. (A) and (B) Comparison of relative CB1 protein expression; (C) and (D) Comparison of relative CB2 protein expression; (E) and (F) Comparison of relative Mfsd2a protein expression; ** p < 0.01, * p < 0.05.

    Article Snippet: Antibodies against cannabinoid receptor 1 (CB1, AI10227475) and P-glycoprotein (P-gp, BA07303498) were purchased from Bioss (Beijing, China).

    Techniques: Expressing, Comparison

    XXD Modulates the P-gp/eCBs Axis in the Hippocampal CA1 Region of SAMP8 Mice; (A) and (B) Comparison of relative P-gp protein expression levels; (C) and (D) Comparison of relative CB1 protein expression levels; (E) and (F) Comparison of relative CB2 protein expression levels; (G) and (H) Immunohistochemical staining for P-gp in the hippocampal CA1 region of mice; (I) and (J) Immunohistochemical staining for CB1 in the hippocampal CA1 region of mice; (K) and (L) Immunohistochemical staining for CB2 in the hippocampal CA1 region of mice; (n = 6); scale bar: 20μm; images captured at ×400 magnification; ** p < 0.01, * p < 0.05.

    Journal: Frontiers in Pharmacology

    Article Title: Xixin Decoction’s novel mechanism for alleviating Alzheimer’s disease cognitive dysfunction by modulating amyloid-β transport across the blood–brain barrier to reduce neuroinflammation

    doi: 10.3389/fphar.2024.1508726

    Figure Lengend Snippet: XXD Modulates the P-gp/eCBs Axis in the Hippocampal CA1 Region of SAMP8 Mice; (A) and (B) Comparison of relative P-gp protein expression levels; (C) and (D) Comparison of relative CB1 protein expression levels; (E) and (F) Comparison of relative CB2 protein expression levels; (G) and (H) Immunohistochemical staining for P-gp in the hippocampal CA1 region of mice; (I) and (J) Immunohistochemical staining for CB1 in the hippocampal CA1 region of mice; (K) and (L) Immunohistochemical staining for CB2 in the hippocampal CA1 region of mice; (n = 6); scale bar: 20μm; images captured at ×400 magnification; ** p < 0.01, * p < 0.05.

    Article Snippet: Antibodies against cannabinoid receptor 1 (CB1, AI10227475) and P-glycoprotein (P-gp, BA07303498) were purchased from Bioss (Beijing, China).

    Techniques: Comparison, Expressing, Immunohistochemical staining, Staining

    FIGURE 3 Mechanisms of the cannabidiol-induced vasorelaxation in isolated human pulmonary arteries. Concentration–response curve of the cannabidiol-induced vaso- relaxation after 30 min incubation (before precontraction) with antagonists of CB1 AM251 (1 mmol/l), CB2 AM630 (1 mmol/l) (a) and endothelium-dependent relaxation to cannabinoids O-1918 (10 mmol/l), TRPV1 capsazepine (1 mmol/l) and TRPV4 RN1734 (20 mmol/l) (b) in endothelium-intact hPAs. The results are presented as the mean SEM of n tissue samples for each curve. In a few cases, SEM is smaller than or equal to the size of symbols. See Table 2 for n and the statistical analysis if not stated here. Representative CB1 (c), CB2 (d), TRPV1 (e) and GPR18 (f) immunoreactivity. Scale bars: 50 mm. hPAs, human pulmonary arteries; SEM, standard error of the mean.

    Journal: Journal of Hypertension

    Article Title: Vasodilatory effects of cannabidiol in human pulmonary and rat small mesenteric arteries: modification by hypertension and the potential pharmacological opportunities

    doi: 10.1097/hjh.0000000000002333

    Figure Lengend Snippet: FIGURE 3 Mechanisms of the cannabidiol-induced vasorelaxation in isolated human pulmonary arteries. Concentration–response curve of the cannabidiol-induced vaso- relaxation after 30 min incubation (before precontraction) with antagonists of CB1 AM251 (1 mmol/l), CB2 AM630 (1 mmol/l) (a) and endothelium-dependent relaxation to cannabinoids O-1918 (10 mmol/l), TRPV1 capsazepine (1 mmol/l) and TRPV4 RN1734 (20 mmol/l) (b) in endothelium-intact hPAs. The results are presented as the mean SEM of n tissue samples for each curve. In a few cases, SEM is smaller than or equal to the size of symbols. See Table 2 for n and the statistical analysis if not stated here. Representative CB1 (c), CB2 (d), TRPV1 (e) and GPR18 (f) immunoreactivity. Scale bars: 50 mm. hPAs, human pulmonary arteries; SEM, standard error of the mean.

    Article Snippet: In the immunohistochemical study, the EnVision method was used according to Baranowska-Kuczko et al. [25] using an antibody against the cannabinoid CB1 receptor [1: 1000; rabbit Anti-CB1 (no cat. ab23703); Abcam, Cambridge, UK], cannabinoid CB2 receptor [1: 200; rabbit Anti-CB2 (no cat. ab3561); Abcam], TPRV1 [1: 1000; rabbit Anti-TRPV1 (no cat. bs-1931R); Bioss Antibodies, Woburn, Massachusetts, USA] and GPR18 [1: 1000; rabbit Anti-GPR18 (no cat. ab150618); Abcam].

    Techniques: Isolation, Concentration Assay, Incubation

    FIGURE 6 Mechanisms of the cannabidiol-induced vasorelaxation in isolated rat small mesenteric arteries. Concentration–response curve of the cannabidiol-induced vasorelaxation after 30 min incubation (before precontraction) with antagonists of CB1 AM251 (1 mmol/l; a–h), CB2 AM630 (1 mmol/l; a–d), TRPV1 capsazepine (1 mmol/l; a–d) in endothelium-intact (a–d) and endothelium-denuded (-ENDO; e–h) rat sMAs. The results are presented as the mean SEM of n tissue samples for each curve. See Table 3 for n and the statistical analysis. In a few cases, SEM is smaller than or equal to the size of symbols. SEM, standard error of the mean; sMAs, small mesenteric arteries.

    Journal: Journal of Hypertension

    Article Title: Vasodilatory effects of cannabidiol in human pulmonary and rat small mesenteric arteries: modification by hypertension and the potential pharmacological opportunities

    doi: 10.1097/hjh.0000000000002333

    Figure Lengend Snippet: FIGURE 6 Mechanisms of the cannabidiol-induced vasorelaxation in isolated rat small mesenteric arteries. Concentration–response curve of the cannabidiol-induced vasorelaxation after 30 min incubation (before precontraction) with antagonists of CB1 AM251 (1 mmol/l; a–h), CB2 AM630 (1 mmol/l; a–d), TRPV1 capsazepine (1 mmol/l; a–d) in endothelium-intact (a–d) and endothelium-denuded (-ENDO; e–h) rat sMAs. The results are presented as the mean SEM of n tissue samples for each curve. See Table 3 for n and the statistical analysis. In a few cases, SEM is smaller than or equal to the size of symbols. SEM, standard error of the mean; sMAs, small mesenteric arteries.

    Article Snippet: In the immunohistochemical study, the EnVision method was used according to Baranowska-Kuczko et al. [25] using an antibody against the cannabinoid CB1 receptor [1: 1000; rabbit Anti-CB1 (no cat. ab23703); Abcam, Cambridge, UK], cannabinoid CB2 receptor [1: 200; rabbit Anti-CB2 (no cat. ab3561); Abcam], TPRV1 [1: 1000; rabbit Anti-TRPV1 (no cat. bs-1931R); Bioss Antibodies, Woburn, Massachusetts, USA] and GPR18 [1: 1000; rabbit Anti-GPR18 (no cat. ab150618); Abcam].

    Techniques: Isolation, Concentration Assay, Incubation

    FIGURE 7 The relative Cnr1 (a) and Cnr2 (b) gene expression evaluated by real-time quantitative PCR in small mesenteric arteries of hypertensive SHR and DOCA-salt vs. normotensive controls WKY and SHAM, respectively. Results are shown mean SEM (n ¼ 6 per group) as relative fold change in mRNA expression in comparison to respective control, where expression level was set as 1. P < 0.01 or P < 0.001 according to the Student’s t-test. DOCA-salt, 11-deoxycorticosterone acetate-salt; SEM, standard error of the mean; SHR, spontaneously hypertensive rats; SHAM, control sham-operated rats; WKY, Wistar–Kyoto.

    Journal: Journal of Hypertension

    Article Title: Vasodilatory effects of cannabidiol in human pulmonary and rat small mesenteric arteries: modification by hypertension and the potential pharmacological opportunities

    doi: 10.1097/hjh.0000000000002333

    Figure Lengend Snippet: FIGURE 7 The relative Cnr1 (a) and Cnr2 (b) gene expression evaluated by real-time quantitative PCR in small mesenteric arteries of hypertensive SHR and DOCA-salt vs. normotensive controls WKY and SHAM, respectively. Results are shown mean SEM (n ¼ 6 per group) as relative fold change in mRNA expression in comparison to respective control, where expression level was set as 1. P < 0.01 or P < 0.001 according to the Student’s t-test. DOCA-salt, 11-deoxycorticosterone acetate-salt; SEM, standard error of the mean; SHR, spontaneously hypertensive rats; SHAM, control sham-operated rats; WKY, Wistar–Kyoto.

    Article Snippet: In the immunohistochemical study, the EnVision method was used according to Baranowska-Kuczko et al. [25] using an antibody against the cannabinoid CB1 receptor [1: 1000; rabbit Anti-CB1 (no cat. ab23703); Abcam, Cambridge, UK], cannabinoid CB2 receptor [1: 200; rabbit Anti-CB2 (no cat. ab3561); Abcam], TPRV1 [1: 1000; rabbit Anti-TRPV1 (no cat. bs-1931R); Bioss Antibodies, Woburn, Massachusetts, USA] and GPR18 [1: 1000; rabbit Anti-GPR18 (no cat. ab150618); Abcam].

    Techniques: Gene Expression, Real-time Polymerase Chain Reaction, Expressing, Comparison, Control

    FIGURE 8 Representative micrographs of immunohistochemical staining of CB1, CB2, TRPV1 and GPR18 receptors in cross-sections of rat small mesenteric arteries from normotensive control (WKY; SHAM) and hypertensive (SHR; DOCA-salt) rats. Scale bars: 50 mm. DOCA-salt, 11-deoxycorticosterone acetate-salt; SHR, spontaneously hypertensive rats; SHAM, control sham-operated rats; WKY, Wistar–Kyoto.

    Journal: Journal of Hypertension

    Article Title: Vasodilatory effects of cannabidiol in human pulmonary and rat small mesenteric arteries: modification by hypertension and the potential pharmacological opportunities

    doi: 10.1097/hjh.0000000000002333

    Figure Lengend Snippet: FIGURE 8 Representative micrographs of immunohistochemical staining of CB1, CB2, TRPV1 and GPR18 receptors in cross-sections of rat small mesenteric arteries from normotensive control (WKY; SHAM) and hypertensive (SHR; DOCA-salt) rats. Scale bars: 50 mm. DOCA-salt, 11-deoxycorticosterone acetate-salt; SHR, spontaneously hypertensive rats; SHAM, control sham-operated rats; WKY, Wistar–Kyoto.

    Article Snippet: In the immunohistochemical study, the EnVision method was used according to Baranowska-Kuczko et al. [25] using an antibody against the cannabinoid CB1 receptor [1: 1000; rabbit Anti-CB1 (no cat. ab23703); Abcam, Cambridge, UK], cannabinoid CB2 receptor [1: 200; rabbit Anti-CB2 (no cat. ab3561); Abcam], TPRV1 [1: 1000; rabbit Anti-TRPV1 (no cat. bs-1931R); Bioss Antibodies, Woburn, Massachusetts, USA] and GPR18 [1: 1000; rabbit Anti-GPR18 (no cat. ab150618); Abcam].

    Techniques: Immunohistochemical staining, Staining, Control